Get your full text copy in PDF
Fas and Fas ligand as prognostic factors in human
breast carcinoma
Marek Bebenek, Danuta Duś, Joanna Koźlak
Med Sci Monit 2006; 12(11): CR457-461
ID: 462574
Background: Several studies on breast cancer patients indicate that Fas/FasL status may have a signifi cant impact on patient survival, but their conclusions are still controversial. The aim of this study was to determine the prognostic value of Fas and Fas ligand (FasL) expressions in the early stages of breast
cancer.
Material/Methods: One hundred and eight patients aged 35–77 years (median: 58), mostly with stage I or II tumors, were analyzed.
Results: Signifi cant associations were noted between Fas expression and lymph node involvement (p
This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree